Pure compound from Boswellia serrata extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNFα, IL-1β, NO and MAP kinases

International Immunopharmacology

Volumn 7, Issue 4, 2007, Pages 473-482

  Gayathri, B ^a   Manjula, N ^a   Vinaykumar, K S ^a   Lakshmi, B S ^a   Balakrishnan, A ^b  

^a ANNA UNIVERSITY   (India)

^b Piramal Enterprises Limited   (India)

Author keywords

Boswellia serrata; c fos; c jun; MAPK; Nitric oxide; Pro inflammatory cytokines

Indexed keywords

12 URSENE 2 DIKETONE; ANTIINFLAMMATORY AGENT; BOSWELLIA SERRATA EXTRACT; CYTOKINE; DIKETONE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA INHIBITOR; INTERLEUKIN 4; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE INHIBITOR; NITRIC OXIDE SYNTHASE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING SITE; BOSWELLIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ISOLATION; ENZYME PHOSPHORYLATION; HUMAN; IMMUNOMODULATION; INHIBITION KINETICS; MEDICINAL PLANT; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BOSWELLIA; CELL LINE; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NITRIC OXIDE; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RNA, MESSENGER;

EID: 33847047219     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.12.003     Document Type: Article

References (55)

1. Pulendran B., Palucka K., and Banchereau J. Sensing pathogens and tuning immune responses. Science 293 (2001) 253-256
2. Luppi P., Rossiello M.R., Faas S., and Trucco M. Genetic background and environment contribute synergistically to the onset of autoimmune diseases. J Mol Med 73 (1995) 381-393
3. Steinman L. Immune therapy for autoimmune diseases. Science 305 (2004) 212-216
4. Krieglstein C.F., Anthoni C., Rijcken E.J., Laukotter M., Spiegel H.U., Boden S.E., et al. Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis 16 (2001) 88
5. Gerhardt H., Seifert F., Buvari P., Vogelsang H., and Repges R. Therapy of active Crohn's disease with Boswellia serrata extract H 15. Z Gastroenterol 39 (2001) 11-17
6. Kimmatkar N., Thawani V., Hingorani L., and Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee-a randomized double blind placebo controlled trial. Phytomedicine 10 (2003) 3-7
7. Dinarello C.A. Proinflammatory cytokines. Chest 118 (2001) 503-508
8. Lamprecht P., Voswinkel J., Lilienthal T., Nolle B., Heller M., Gross W.L., et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology 41 (2002) 1303-1307
9. Stichtenoth D.O., and Frolich J.C. Nitric oxide and inflammatory joint diseases. Br J Rheumatol 37 (1998) 246-257
10. Clancy R.M., Amin A.R., and Abramson S.B. The role of nitric oxide in inflammation and immunity. Arthritis Rheum 41 (1998) 1141-1151
11. Ji Young Kim, Kyung Sik Jung, and Hye Gwang Jeong. Suppressive effects of the kahweol and cafestol on cyclooxygenase-2 expression in macrophages. FEBS Lett 569 (2004) 321-326
12. Raso G.M., Meli R., Di Carlo G., Pacilio M., and Di Carlo R. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life Sci 68 (2001) 921-931
13. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13 (1995) 251-276
14. Nelms K., Keegan A.D., Zamorano J., Ryan J.J., and Paul W.E. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 17 (1999) 701-738
15. Romagnani P., Annunziato F., Piccinni M.P., Maggi E., and Romagnani S. Th1/Th2 cells, their associated molecules and role in pathophysiology. Eur Cytokine Netw 11 (2000) 510-511
16. Vodovotz Y., Bogdn C., Paik J., Xie O.W., and Nathan C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J Exp Med 178 (1993) 605-613
17. Rao K.M. Molecular mechanisms regulating iNOS expression in various cell types. J Toxicol Environ Health B Crit Rev 3 (2000) 27-58
18. Dong C., Davis R.J., and Flavell R.A. MAP kinases in the immune response. Annu Rev Immunol 20 (2002) 55-72
19. Swantek J.L., Cobb M.H., and Geppert T.D. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol Cell Biol 17 (1997) 6274-6282
20. Rao K.M., Meighan T., and Bowman L. Role of mitogen-activated protein kinase activation in the production of inflammatory mediators: differences between primary rat alveolar macrophages and macrophage cell lines. J Toxicol Environ Health A 65 (2002) 757-768
21. Kyriakis J.M., and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81 (2001) 807-869
22. Rao K.M. MAP kinase activation in macrophages. J Leukoc Biol 69 (2001) 3-10
23. Dumont F.J., Staruch M.J., Fischer P., DaSilva C., and Camacho R. Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J Immunol 160 (1998) 2579-2589
24. Su B., Jacinto E., Hibi M., Kallunki T., Karin M., and Ben-Neriah Y. JNK is involved in signal integration during costimulation of T lymphocytes. Cell 77 (1994) 727-736
25. Rau B., Kruger C., Paszkowsky A.S., Lillich S., Mayer J.M., Moller P., et al. Effects of FK 506 on pancreatic acinar cell damage in taurocholate induced acute experimental pancreatitis. Pancreatology 1 (2001) 129
26. Bessler H., Mendel C., Straussberg R., Gurary N., Aloni D., and Sirota L. Effects of dexamethasone on IL-1, IL-6, and TNF - production by mononuclear cells of newborns and adults. Biol Neonate 75 (1999) 225-233
27. Rahman I., and Adcock I.M. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 28 (2006) 219-242
28. Singh U., Devaraj S., and Jialal I. Vitamin E, oxidative stress, and inflammation. Annu Rev Nutr 25 (2005) 151-174
29. Newton R.C., and Decicco C.P. Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha. J of Med Chem 42 (1999) 2295-2314
30. Noguchi M., Hiwatashi N., Liu Z., and Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut 43 (1999) 203-209
31. Kontoyiannis D., Pasparakis M., Pizarro T.T., Cominelli F., and Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10 (1999) 387-398
32. Perkins D.J., and Kniss D.A. Tumor necrosis factor-alpha promotes sustained cyclooxygenase-2 expression: attenuation by dexamethasone and NSAIDs. Prostaglandins 54 (1997) 727-743
33. Perkins D.J., St Clair E.W., Misukonis M.A., and Weinberg J.B. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2). Arthritis Rheum 41 (1998) 2205-2210
34. Wong H.R., Finder J.D., Wasserloos K., Lowenstein C.J., Geller D.A., Billiar T.R., et al. Transcriptional regulation of iNOS by IL-1 beta in cultured rat pulmonary artery smooth muscle cells. Am J Physiol 271 (1996) L166-L171
35. Dinarello C.A. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20 (2002) S1-S13
36. Dinarello C.A. Blocking interleukin-1 and tumor necrosis factor in disease. Eur Cytokine Netw 8 (1997) 294-296
37. Meng F., and Lowell C.A. Lipopolysaccharide (LPS)-induced macrophage activation and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn. J Exp Med 185 (1997) 1661-1670
38. Miossec P., Briolay J., Dechanet J., Wijdenes J., Martinez-Valdez H., and Banchereau J. Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis. Arthritis Rheum 35 (1992) 874-878
39. Mueller R., Krahl T., and Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 184 (1996) 1093-1099
40. Liblau R.S., Singer S.M., and McDevitt H.O. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunology Today 16 (1995) 34-38
41. Bessis N., Fradelizi D., Fournier C., and Boissier M.C. Treatment of inflammation with anti-inflammatory cytokines: example in models of auto-immune diseases. Comptes Rendusdes Seances de la Societe de Biologie et de ses Filiales vol. 189 (1996) 579-590
42. Southey A., Tanaka S., Murakam T., Miyoshi H., Ishizuka T., Sugiura M., et al. Pathophysiological role of nitric oxide in rat experimental colitis. Int J Immunopharmacol 19 (1997) 669-676
43. Chen C.Y., Del Gatto-Konczak F., Wu Z., and Karin M. Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase pathway. Science 280 (1998) 1945-1949
44. Swantek J.L., Cobb M.H., and Geppert T.D. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol Cell Biol 17 (1997) 6274-6282
45. Ip Y.T., and Davis R.J. Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr Opin Cell Biol 10 (1998) 205-219
46. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., and Griswold D.E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 279 (1996) 1453-1461
47. Hallsworth M.P., Moir L.M., Lai D., and Hirst S.J. Inhibitors of mitogen-activated protein kinases differentially regulate eosinophil-activating cytokine release from human airway smooth muscle. Am J Respir Crit Care Med 164 (2001) 688-697
48. Hommes D., van den Blink B., Plasse T., Bartelsman J., Xu C., Macpherson B., et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122 (2002) 7-14
49. Hommes D.W., Peppelenbosch M.P., and van Deventer S.J. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 52 (2003) 144-151
50. Cook S.J., Aziz N., and McMahon M. The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation. Mol Cell Biol 19 (1999) 330-341
51. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270 (1995) 16483-16486
52. Whitmarsh A.J., and Davis R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74 (1996) 589-607
53. Derijard B., Hibi M., Wu I.H., Barrett T., Su B., Deng T., et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76 (1991) 1025-1037
54. Han Z., Boyle D.L., Chang L., Bennett B., Karin M., Yang L., et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 108 (2001) 73-81
55. Vincenti M.P., and Brinckerhoff C.E. The potential of signal transduction inhibitors for the treatment of arthritis: Is it all just JNK?. J Clin Invest 108 (2001) 181-183